Table 1 Studies of the maturation of broadly neutralizing antibodies
From: Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
Epitope | Donor | Sampling | Ab lineage | Breadth Median IC50 | VH-gene SHM (%nt) | VL-gene | CDR3 length | Indels | Poly/autoreactivity | Viral subtype | Viral sequencing | UCA binds/neutralizes T/F | References |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CD4bs | NIH45 | Chronic | VRC01 | 89%; 0.3 µg/mL | VH1-2 32% | VK3-20 | H: 14 aa L: 5 aa | Yes Del CDRL1 | + | B | No | ||
DRVI01 | Chronic | DRVIA7 | < 10% | VH1-2 19% | VK1-5 | H: 13 aa L: 5 aa | No | B | Yes | [120] | |||
CH505 | Longitudinal | CH103 | 55%; 4.54 µg/mL | VH4-59 14% | VL3-1 | H: 15 aa L: 10 aa | Yes Del CDRL1 | ++ | C | Yes | Neutralization | [58] | |
CH505 | Longitudinal | CH235 | 90%; 0.6 µg/mL | VH1-46 28% | VK3-15 | H: 15 aa L: 8 aa | No | ++ | C | Yes | Weak binding | ||
N60 | Chronic | N60P25.1 | 73% | VH1-2 33% | VK1-5 | H: 13aa L: 5 aa | No | B | No | [125] | |||
N49 | Chronic | N49P7 | 98%; 0.1 µg/mL | VH1-2 33% | VL2-11 | H: 19aa L: 5 aa | Yes Del CDRL1 | B | No | [125] | |||
PC063 | Longitudinal | PCIN63 | 80%; 0.24 µg/mL | VH1-2 15% | VK1-5 | H: 15 aa L: 5 aa | No | Variable | C | Yes | No binding | Landais et al. (unpublished) | |
V2-glycan | CAP256 | Longitudinal | VRC26-CAP256 | 63%; 0.003 µg/mL | VH3-30 12% | VL1-51 | H: 36 aa L: 13 aa | No | – | C | Yes | Neutralization | |
PC064 | Longitudinal | PCT64 | 37%; 0.42 µg/mL | VH3-15 13% | VK3-20 | H: 25aa L: 8 aa | No | ± | A | Yes | Binding of 293S-expressed Env | . | |
V3-glycan | PC076 | Longitudinal | PCDN | 47%; 0.53 µg/mL | VH4-34 16% | VK3-20 | H: 22 aa L: 8aa | No | ± | C | Yes | No binding | [59] |
PC039 | Longitudinal | PCN39 | 45%; 0.03 µg/mL | VH4-34 16% | VK3-20 | H: 22 aa L: 10aa | Yes Ins CDRH1 | ++ | C | Yes | No binding | Murrell, Landais et al. (unpublished) | |
BF520 | Longitudinal (Infant) | BF520.1 | 58%; 1.95 µg/mL | VH1-2 7% | VK3-15 | H: 20 aa L: 7aa | No | A | Yes | Cell surface binding | [80] | ||
CH848 | Longitudinal | DH270 | 55%; 0.08 µg/mL | VH1-2 13% | VL2-23 | H: 20aa L: 9 aa | No | ± | C | Yes | Weak binding | [102] | |
MPER | N152 | Chronic | 10E8 | 98%; 0.35 µg/mL | VH3-15 21% | VL3-19 | H: 22 aa L: 11 aa | No | – | B | No | [149] | |
CH0210 | Chronic | DH511 | 99%; 1.04 µg/mL | VH3-15 18% | VK1-39 | H: 22 aa L: 11 aa | No | ++ | C | No | [150] |